Low incidence of retinopathy during peginterferon alpha-2b and lamivudine therapy for chronic hepatitis B.
Buster
Erik H C J
EH
Ter Borg
Martijn J
MJ
Vingerling
Johannes R
JR
Janssen
Harry L A
HL
D000998:Antiviral Agents / Q000009:adverse effects*; D005074:Evoked Potentials, Visual / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D019259:Lamivudine / Q000009:adverse effects* / Q000627:therapeutic use; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012164:Retinal Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000503:physiopathology; D012307:Risk Factors
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019259:Lamivudine; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b